{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:30:31Z","timestamp":1790739031068,"version":"4.1.0"},"reference-count":112,"publisher":"Harborside Press, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and\/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States.\n                    <jats:sup>1<\/jats:sup>\n                    The NCCN Guidelines Panel for AML convenes annually to update recommendations for the diagnosis and treatment of AML in adults. These recommendations are based on a review of recently published clinical trials that have led to significant improvements in treatment or have yielded new information regarding biologic factors that may have prognostic importance. These NCCN Guidelines Insights summarize the panel\u2019s most recent recommendations regarding the monitoring and management of measurable (minimal) residual disease.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2026.0028","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:47:46Z","timestamp":1781527666000},"page":"222-229","source":"Crossref","is-referenced-by-count":1,"title":["NCCN Guidelines\u00ae Insights: Acute Myeloid Leukemia, Version 3.2026"],"prefix":"10.6004","volume":"24","author":[{"given":"Daniel A.","family":"Pollyea","sequence":"first","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Altman","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Assi","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimo","family":"Bachiashvili","sequence":"additional","affiliation":[{"name":"O\u2019Neil Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya Raj","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Fedorov","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Foran","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Gojo","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aric C.","family":"Hall","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Jonas","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Levine","sequence":"additional","affiliation":[{"name":"Patient Advocate"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mangan","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Mannis","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Mims","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Moriarty","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moaath","family":"Mustafa Ali","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadee","family":"Neff","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Nejati","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Olin","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Patel","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Elizabeth","family":"Percival","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Perl","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Pettit","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Rao","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaker","family":"Schwabkey","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Shallis","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapna","family":"Thota","sequence":"additional","affiliation":[{"name":"St. Jude Children's Research Hospital\/The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey L.","family":"Uy","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Walker","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Wang","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajibola","family":"Awotiwon","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney L.","family":"Roth","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Stehman","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN,  Cancer statistics, 2025. CA Cancer J Clin 2025;75:10\u201345."},{"key":"B2","series-title":"Blood","first-page":"1275","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis GJ","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S,  Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018;131:1275\u20131291."},{"key":"B3","series-title":"JAMA Oncol","first-page":"1890","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short NJ","year":"2020","unstructured":"Short NJ, Zhou S, Fu C,  Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol 2020;6:1890\u20131899."},{"key":"B4","series-title":"J Clin Oncol","first-page":"495","article-title":"Modern approaches to treating acute promyelocytic leukemia","volume":"29","author":"Sanz MA","year":"2011","unstructured":"Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 2011;29:495\u2013503."},{"key":"B5","series-title":"Leuk Res","first-page":"3","article-title":"Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?","volume":"35","author":"Grimwade D","year":"2011","unstructured":"Grimwade D, Tallman MS. Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia? Leuk Res 2011;35:3\u20137."},{"key":"B6","series-title":"Blood Adv","first-page":"1356","article-title":"Evaluating measurable residual disease in acute myeloid leukemia","volume":"2","author":"Ravandi F","year":"2018","unstructured":"Ravandi F, Walter RB, Freeman SD. Evaluating measurable residual disease in acute myeloid leukemia. Blood Adv 2018;2:1356\u20131366."},{"key":"B7","series-title":"Clin Lymphoma Myeloma","first-page":"S281","article-title":"Minimal residual disease quantitation in acute myeloid leukemia","volume":"9","author":"Shook D","year":"2009","unstructured":"Shook D, Coustan-Smith E, Ribeiro RC,  Minimal residual disease quantitation in acute myeloid leukemia. Clin Lymphoma Myeloma 2009;9(Suppl 3):S281\u2013285."},{"key":"B8","series-title":"Curr Opin Oncol","first-page":"656","article-title":"Assessment of minimal residual disease in acute myeloid leukemia","volume":"22","author":"Grimwade D","year":"2010","unstructured":"Grimwade D, Vyas P, Freeman S. Assessment of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol 2010;22:656\u2013663."},{"key":"B9","series-title":"Blood","first-page":"332","article-title":"Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia","volume":"119","author":"Buccisano F","year":"2012","unstructured":"Buccisano F, Maurillo L, Del Principe MI,  Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012;119:332\u2013341."},{"key":"B10","series-title":"N Engl J Med","first-page":"1189","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic M","year":"2018","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D,  Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med 2018;378:1189\u20131199."},{"key":"B11","series-title":"JAMA","first-page":"811","article-title":"Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia","volume":"314","author":"Klco JM","year":"2015","unstructured":"Klco JM, Miller CA, Griffith M,  Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA 2015;314:811\u2013822."},{"key":"B12","series-title":"Blood","first-page":"354","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade D","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV,  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354\u2013365."},{"key":"B13","series-title":"J Clin Oncol","first-page":"2674","article-title":"Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12","volume":"28","author":"Harrison CJ","year":"2010","unstructured":"Harrison CJ, Hills RK, Moorman AV,  Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol 2010;28:2674\u20132681."},{"key":"B14","series-title":"Leuk Lymphoma","first-page":"517","article-title":"A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse","volume":"49","author":"Lane S","year":"2008","unstructured":"Lane S, Saal R, Mollee P,  A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. Leuk Lymphoma 2008;49:517\u2013523."},{"key":"B15","series-title":"J Clin Oncol","first-page":"3724","article-title":"Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia","volume":"28","author":"Corbacioglu A","year":"2010","unstructured":"Corbacioglu A, Scholl C, Schlenk RF,  Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol 2010;28:3724\u20133729."},{"key":"B16","series-title":"Blood","first-page":"2826","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Yin JA","year":"2012","unstructured":"Yin JA, O\u2019Brien MA, Hills RK,  Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 2012;120:2826\u20132835."},{"key":"B17","series-title":"Leukemia","first-page":"1130","article-title":"Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1\/ETO rearrangement","volume":"17","author":"Viehmann S","year":"2003","unstructured":"Viehmann S, Teigler-Schlegel A, Bruch J,  Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1\/ETO rearrangement. Leukemia 2003;17:1130\u20131136."},{"key":"B18","series-title":"Haematologica","first-page":"1626","article-title":"The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia","volume":"90","author":"Scholl C","year":"2005","unstructured":"Scholl C, Schlenk RF, Eiwen K,  The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. Haematologica 2005;90:1626\u20131634."},{"key":"B19","series-title":"Blood","first-page":"1862","article-title":"Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML","volume":"146","author":"Othman J","year":"2025","unstructured":"Othman J, Potter N, Freeman SD,  Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML. Blood 2025;146:1862\u20131867."},{"key":"B20","series-title":"J Clin Oncol","first-page":"3625","article-title":"Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia","volume":"30","author":"Inaba H","year":"2012","unstructured":"Inaba H, Coustan-Smith E, Cao X,  Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol 2012;30:3625\u20133632."},{"key":"B21","series-title":"Blood","first-page":"1147","article-title":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party","volume":"147","author":"Cloos J","year":"2026","unstructured":"Cloos J, Valk PJM, Thiede C,  2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party. Blood 2026;147:1147\u20131167."},{"key":"B22","series-title":"Leukemia","first-page":"1408","article-title":"Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting","volume":"15","author":"Varella-Garcia M","year":"2001","unstructured":"Varella-Garcia M, Hogan CJ, Odom LF,  Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting. Leukemia 2001;15:1408\u20131414."},{"key":"B23","series-title":"Blood","first-page":"4205","article-title":"Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3\/ITD AML","volume":"120","author":"Sexauer A","year":"2012","unstructured":"Sexauer A, Perl A, Yang X,  Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3\/ITD AML. Blood 2012;120:4205\u20134214."},{"key":"B24","series-title":"J Clin Oncol","first-page":"1788","article-title":"Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia","volume":"36","author":"Morita K","year":"2018","unstructured":"Morita K, Kantarjian HM, Wang F,  Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia. J Clin Oncol 2018;36:1788\u20131797."},{"key":"B25","series-title":"Clin Chim Acta","first-page":"120","article-title":"Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression","volume":"395","author":"Barragan E","year":"2008","unstructured":"Barragan E, Pajuelo JC, Ballester S,  Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression. Clin Chim Acta 2008;395:120\u2013123."},{"key":"B26","series-title":"Leukemia","first-page":"1103","article-title":"Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations","volume":"20","author":"Gorello P","year":"2006","unstructured":"Gorello P, Cazzaniga G, Alberti F,  Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006;20:1103\u20131108."},{"key":"B27","series-title":"N Engl J Med","first-page":"422","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey A","year":"2016","unstructured":"Ivey A, Hills RK, Simpson MA,  Assessment of minimal residual disease in standard-risk AML. N Engl J Med 2016;374:422\u2013433."},{"key":"B28","series-title":"Eur J Haematol","first-page":"400","article-title":"NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression","volume":"87","author":"Kristensen T","year":"2011","unstructured":"Kristensen T, Moller MB, Friis L,  NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression. Eur J Haematol 2011;87:400\u2013408."},{"key":"B29","series-title":"Leuk Lymphoma","first-page":"2214","article-title":"Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression","volume":"53","author":"Miglino M","year":"2012","unstructured":"Miglino M, Colombo N, Grasso R,  Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression. Leuk Lymphoma 2012;53:2214\u20132217."},{"key":"B30","series-title":"Br J Haematol","first-page":"517","article-title":"Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor","volume":"144","author":"Papadaki C","year":"2009","unstructured":"Papadaki C, Dufour A, Seibl M,  Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Br J Haematol 2009;144:517\u2013523."},{"key":"B31","series-title":"Blood","first-page":"2220","article-title":"Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML","volume":"114","author":"Schnittger S","year":"2009","unstructured":"Schnittger S, Kern W, Tschulik C,  Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009;114:2220\u20132231."},{"key":"B32","series-title":"Leuk Lymphoma","first-page":"1837","article-title":"Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis","volume":"51","author":"Stahl T","year":"2010","unstructured":"Stahl T, Badbaran A, Kroger N,  Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis. Leuk Lymphoma 2010;51:1837\u20131843."},{"key":"B33","series-title":"Blood","first-page":"59","article-title":"Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease","volume":"100","author":"Schnittger S","year":"2002","unstructured":"Schnittger S, Schoch C, Dugas M,  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59\u201366."},{"key":"B34","series-title":"Br J Haematol","first-page":"103","article-title":"Development of a quantitative real-time polymerase chain reaction method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemia","volume":"133","author":"Smith LL","year":"2006","unstructured":"Smith LL, Pearce D, Smith ML,  Development of a quantitative real-time polymerase chain reaction method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemia. Br J Haematol 2006;133:103\u2013105."},{"key":"B35","series-title":"Haematologica","first-page":"881","article-title":"Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy","volume":"90","author":"Weisser M","year":"2005","unstructured":"Weisser M, Kern W, Schoch C,  Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. Haematologica 2005;90:881\u2013889."},{"key":"B36","series-title":"JAMA","first-page":"745","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon LW","year":"2023","unstructured":"Dillon LW, Gui G, Page KM,  DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant. JAMA 2023;329:745\u2013755."},{"key":"B37","series-title":"J Clin Oncol","first-page":"1766","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis MJ","year":"2024","unstructured":"Levis MJ, Hamadani M, Logan B,  Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol 2024;42:1766\u20131775."},{"key":"B38","series-title":"Blood","first-page":"3948","article-title":"Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia","volume":"96","author":"Venditti A","year":"2000","unstructured":"Venditti A, Buccisano F, Del Poeta G,  Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000;96:3948\u20133952."},{"key":"B39","series-title":"Blood","first-page":"1581","article-title":"Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group","volume":"120","author":"Loken MR","year":"2012","unstructured":"Loken MR, Alonzo TA, Pardo L,  Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood 2012;120:1581\u20131588."},{"key":"B40","series-title":"J Clin Oncol","first-page":"329","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?","volume":"34","author":"Araki D","year":"2016","unstructured":"Araki D, Wood BL, Othus M,  Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol 2016;34:329\u2013336."},{"key":"B41","series-title":"Leukemia","first-page":"1783","article-title":"The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia","volume":"20","author":"Buccisano F","year":"2006","unstructured":"Buccisano F, Maurillo L, Gattei V,  The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 2006;20:1783\u20131789."},{"key":"B42","series-title":"J Clin Oncol","first-page":"4944","article-title":"Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia","volume":"26","author":"Maurillo L","year":"2008","unstructured":"Maurillo L, Buccisano F, Del Principe MI,  Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008;26:4944\u20134951."},{"key":"B43","series-title":"Haematologica","first-page":"605","article-title":"Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow","volume":"92","author":"Maurillo L","year":"2007","unstructured":"Maurillo L, Buccisano F, Spagnoli A,  Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. Haematologica 2007;92:605\u2013611."},{"key":"B44","series-title":"Cytometry B Clin Cytom","first-page":"91","article-title":"The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse","volume":"76","author":"Al-Mawali A","year":"2009","unstructured":"Al-Mawali A, Gillis D, Lewis I. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Cytometry B Clin Cytom 2009;76:91\u2013101."},{"key":"B45","series-title":"Blood Cancer J","first-page":"e129","article-title":"Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting","volume":"3","author":"Feller N","year":"2013","unstructured":"Feller N, van der Velden VH, Brooimans RA,  Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting. Blood Cancer J 2013;3:e129."},{"key":"B46","series-title":"Leuk Lymphoma","first-page":"80","article-title":"Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia","volume":"48","author":"Voskova D","year":"2007","unstructured":"Voskova D, Schnittger S, Schoch C,  Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia. Leuk Lymphoma 2007;48:80\u201388."},{"key":"B47","series-title":"Blood","first-page":"2213","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan E","year":"2013","unstructured":"Jourdan E, Boissel N, Chevret S,  Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 2013;121:2213\u20132223."},{"key":"B48","series-title":"Haematologica","first-page":"328","article-title":"Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial","volume":"101","author":"Willekens C","year":"2016","unstructured":"Willekens C, Blanchet O, Renneville A,  Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. Haematologica 2016;101:328\u2013335."},{"key":"B49","series-title":"Blood","first-page":"1703","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol F","year":"2018","unstructured":"Thol F, Gabdoulline R, Liebich A,  Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood 2018;132:1703\u20131713."},{"key":"B50","series-title":"Blood","first-page":"1608","article-title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group","volume":"134","author":"Rucker FG","year":"2019","unstructured":"Rucker FG, Agrawal M, Corbacioglu A,  Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. Blood 2019;134:1608\u20131618."},{"key":"B51","series-title":"Haematologica","first-page":"56","article-title":"Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia","volume":"106","author":"Puckrin R","year":"2021","unstructured":"Puckrin R, Atenafu EG, Claudio JO,  Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. Haematologica 2021;106:56\u201363."},{"key":"B52","series-title":"J Clin Oncol","first-page":"855","article-title":"Measurable residual disease response and prognosis in treatment-naive acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz KW","year":"2022","unstructured":"Pratz KW, Jonas BA, Pullarkat V,  Measurable residual disease response and prognosis in treatment-naive acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol 2022;40:855\u2013865."},{"key":"B53","series-title":"Blood","first-page":"336","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman J","year":"2024","unstructured":"Othman J, Tiong IS, O\u2019Nions J,  Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy. Blood 2024;143:336\u2013341."},{"key":"B54","series-title":"Blood","first-page":"1931","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman J","year":"2024","unstructured":"Othman J, Potter N, Ivey A,  Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 2024;143:1931\u20131936."},{"key":"B55","series-title":"J Clin Oncol","first-page":"2161","article-title":"Targeting molecular measurable residual disease and low-blast relapse in AML with venetoclax and low-dose cytarabine: a prospective phase II study (VALDAC)","volume":"42","author":"Tiong IS","year":"2024","unstructured":"Tiong IS, Hiwase DK, Abro E,  Targeting molecular measurable residual disease and low-blast relapse in AML with venetoclax and low-dose cytarabine: a prospective phase II study (VALDAC). J Clin Oncol 2024;42:2161\u20132173."},{"key":"B56","series-title":"J Clin Oncol","first-page":"2993","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert A","year":"2020","unstructured":"Burchert A, Bug G, Fritz LV,  Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol 2020;38:2993\u20133002."},{"key":"B1","series-title":"CA Cancer J Clin","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN,  Cancer statistics, 2025. CA Cancer J Clin 2025;75:10\u201345."},{"key":"B2","series-title":"Blood","first-page":"1275","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis GJ","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S,  Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018;131:1275\u20131291."},{"key":"B3","series-title":"JAMA Oncol","first-page":"1890","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short NJ","year":"2020","unstructured":"Short NJ, Zhou S, Fu C,  Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol 2020;6:1890\u20131899."},{"key":"B4","series-title":"J Clin Oncol","first-page":"495","article-title":"Modern approaches to treating acute promyelocytic leukemia","volume":"29","author":"Sanz MA","year":"2011","unstructured":"Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 2011;29:495\u2013503."},{"key":"B5","series-title":"Leuk Res","first-page":"3","article-title":"Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?","volume":"35","author":"Grimwade D","year":"2011","unstructured":"Grimwade D, Tallman MS. Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia? Leuk Res 2011;35:3\u20137."},{"key":"B6","series-title":"Blood Adv","first-page":"1356","article-title":"Evaluating measurable residual disease in acute myeloid leukemia","volume":"2","author":"Ravandi F","year":"2018","unstructured":"Ravandi F, Walter RB, Freeman SD. Evaluating measurable residual disease in acute myeloid leukemia. Blood Adv 2018;2:1356\u20131366."},{"key":"B7","series-title":"Clin Lymphoma Myeloma","first-page":"S281","article-title":"Minimal residual disease quantitation in acute myeloid leukemia","volume":"9","author":"Shook D","year":"2009","unstructured":"Shook D, Coustan-Smith E, Ribeiro RC,  Minimal residual disease quantitation in acute myeloid leukemia. Clin Lymphoma Myeloma 2009;9(Suppl 3):S281\u2013285."},{"key":"B8","series-title":"Curr Opin Oncol","first-page":"656","article-title":"Assessment of minimal residual disease in acute myeloid leukemia","volume":"22","author":"Grimwade D","year":"2010","unstructured":"Grimwade D, Vyas P, Freeman S. Assessment of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol 2010;22:656\u2013663."},{"key":"B9","series-title":"Blood","first-page":"332","article-title":"Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia","volume":"119","author":"Buccisano F","year":"2012","unstructured":"Buccisano F, Maurillo L, Del Principe MI,  Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012;119:332\u2013341."},{"key":"B10","series-title":"N Engl J Med","first-page":"1189","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic M","year":"2018","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D,  Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med 2018;378:1189\u20131199."},{"key":"B11","series-title":"JAMA","first-page":"811","article-title":"Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia","volume":"314","author":"Klco JM","year":"2015","unstructured":"Klco JM, Miller CA, Griffith M,  Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA 2015;314:811\u2013822."},{"key":"B12","series-title":"Blood","first-page":"354","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade D","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV,  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354\u2013365."},{"key":"B13","series-title":"J Clin Oncol","first-page":"2674","article-title":"Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12","volume":"28","author":"Harrison CJ","year":"2010","unstructured":"Harrison CJ, Hills RK, Moorman AV,  Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol 2010;28:2674\u20132681."},{"key":"B14","series-title":"Leuk Lymphoma","first-page":"517","article-title":"A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse","volume":"49","author":"Lane S","year":"2008","unstructured":"Lane S, Saal R, Mollee P,  A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. Leuk Lymphoma 2008;49:517\u2013523."},{"key":"B15","series-title":"J Clin Oncol","first-page":"3724","article-title":"Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia","volume":"28","author":"Corbacioglu A","year":"2010","unstructured":"Corbacioglu A, Scholl C, Schlenk RF,  Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol 2010;28:3724\u20133729."},{"key":"B16","series-title":"Blood","first-page":"2826","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Yin JA","year":"2012","unstructured":"Yin JA, O\u2019Brien MA, Hills RK,  Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 2012;120:2826\u20132835."},{"key":"B17","series-title":"Leukemia","first-page":"1130","article-title":"Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1\/ETO rearrangement","volume":"17","author":"Viehmann S","year":"2003","unstructured":"Viehmann S, Teigler-Schlegel A, Bruch J,  Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1\/ETO rearrangement. Leukemia 2003;17:1130\u20131136."},{"key":"B18","series-title":"Haematologica","first-page":"1626","article-title":"The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia","volume":"90","author":"Scholl C","year":"2005","unstructured":"Scholl C, Schlenk RF, Eiwen K,  The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. Haematologica 2005;90:1626\u20131634."},{"key":"B19","series-title":"Blood","first-page":"1862","article-title":"Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML","volume":"146","author":"Othman J","year":"2025","unstructured":"Othman J, Potter N, Freeman SD,  Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML. Blood 2025;146:1862\u20131867."},{"key":"B20","series-title":"J Clin Oncol","first-page":"3625","article-title":"Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia","volume":"30","author":"Inaba H","year":"2012","unstructured":"Inaba H, Coustan-Smith E, Cao X,  Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol 2012;30:3625\u20133632."},{"key":"B21","series-title":"Blood","first-page":"1147","article-title":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party","volume":"147","author":"Cloos J","year":"2026","unstructured":"Cloos J, Valk PJM, Thiede C,  2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party. Blood 2026;147:1147\u20131167."},{"key":"B22","series-title":"Leukemia","first-page":"1408","article-title":"Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting","volume":"15","author":"Varella-Garcia M","year":"2001","unstructured":"Varella-Garcia M, Hogan CJ, Odom LF,  Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting. Leukemia 2001;15:1408\u20131414."},{"key":"B23","series-title":"Blood","first-page":"4205","article-title":"Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3\/ITD AML","volume":"120","author":"Sexauer A","year":"2012","unstructured":"Sexauer A, Perl A, Yang X,  Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3\/ITD AML. Blood 2012;120:4205\u20134214."},{"key":"B24","series-title":"J Clin Oncol","first-page":"1788","article-title":"Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia","volume":"36","author":"Morita K","year":"2018","unstructured":"Morita K, Kantarjian HM, Wang F,  Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia. J Clin Oncol 2018;36:1788\u20131797."},{"key":"B25","series-title":"Clin Chim Acta","first-page":"120","article-title":"Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression","volume":"395","author":"Barragan E","year":"2008","unstructured":"Barragan E, Pajuelo JC, Ballester S,  Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression. Clin Chim Acta 2008;395:120\u2013123."},{"key":"B26","series-title":"Leukemia","first-page":"1103","article-title":"Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations","volume":"20","author":"Gorello P","year":"2006","unstructured":"Gorello P, Cazzaniga G, Alberti F,  Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006;20:1103\u20131108."},{"key":"B27","series-title":"N Engl J Med","first-page":"422","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey A","year":"2016","unstructured":"Ivey A, Hills RK, Simpson MA,  Assessment of minimal residual disease in standard-risk AML. N Engl J Med 2016;374:422\u2013433."},{"key":"B28","series-title":"Eur J Haematol","first-page":"400","article-title":"NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression","volume":"87","author":"Kristensen T","year":"2011","unstructured":"Kristensen T, Moller MB, Friis L,  NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression. Eur J Haematol 2011;87:400\u2013408."},{"key":"B29","series-title":"Leuk Lymphoma","first-page":"2214","article-title":"Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression","volume":"53","author":"Miglino M","year":"2012","unstructured":"Miglino M, Colombo N, Grasso R,  Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression. Leuk Lymphoma 2012;53:2214\u20132217."},{"key":"B30","series-title":"Br J Haematol","first-page":"517","article-title":"Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor","volume":"144","author":"Papadaki C","year":"2009","unstructured":"Papadaki C, Dufour A, Seibl M,  Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Br J Haematol 2009;144:517\u2013523."},{"key":"B31","series-title":"Blood","first-page":"2220","article-title":"Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML","volume":"114","author":"Schnittger S","year":"2009","unstructured":"Schnittger S, Kern W, Tschulik C,  Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009;114:2220\u20132231."},{"key":"B32","series-title":"Leuk Lymphoma","first-page":"1837","article-title":"Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis","volume":"51","author":"Stahl T","year":"2010","unstructured":"Stahl T, Badbaran A, Kroger N,  Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis. Leuk Lymphoma 2010;51:1837\u20131843."},{"key":"B33","series-title":"Blood","first-page":"59","article-title":"Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease","volume":"100","author":"Schnittger S","year":"2002","unstructured":"Schnittger S, Schoch C, Dugas M,  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59\u201366."},{"key":"B34","series-title":"Br J Haematol","first-page":"103","article-title":"Development of a quantitative real-time polymerase chain reaction method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemia","volume":"133","author":"Smith LL","year":"2006","unstructured":"Smith LL, Pearce D, Smith ML,  Development of a quantitative real-time polymerase chain reaction method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemia. Br J Haematol 2006;133:103\u2013105."},{"key":"B35","series-title":"Haematologica","first-page":"881","article-title":"Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy","volume":"90","author":"Weisser M","year":"2005","unstructured":"Weisser M, Kern W, Schoch C,  Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. Haematologica 2005;90:881\u2013889."},{"key":"B36","series-title":"JAMA","first-page":"745","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon LW","year":"2023","unstructured":"Dillon LW, Gui G, Page KM,  DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant. JAMA 2023;329:745\u2013755."},{"key":"B37","series-title":"J Clin Oncol","first-page":"1766","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis MJ","year":"2024","unstructured":"Levis MJ, Hamadani M, Logan B,  Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol 2024;42:1766\u20131775."},{"key":"B38","series-title":"Blood","first-page":"3948","article-title":"Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia","volume":"96","author":"Venditti A","year":"2000","unstructured":"Venditti A, Buccisano F, Del Poeta G,  Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000;96:3948\u20133952."},{"key":"B39","series-title":"Blood","first-page":"1581","article-title":"Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group","volume":"120","author":"Loken MR","year":"2012","unstructured":"Loken MR, Alonzo TA, Pardo L,  Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood 2012;120:1581\u20131588."},{"key":"B40","series-title":"J Clin Oncol","first-page":"329","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?","volume":"34","author":"Araki D","year":"2016","unstructured":"Araki D, Wood BL, Othus M,  Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol 2016;34:329\u2013336."},{"key":"B41","series-title":"Leukemia","first-page":"1783","article-title":"The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia","volume":"20","author":"Buccisano F","year":"2006","unstructured":"Buccisano F, Maurillo L, Gattei V,  The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 2006;20:1783\u20131789."},{"key":"B42","series-title":"J Clin Oncol","first-page":"4944","article-title":"Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia","volume":"26","author":"Maurillo L","year":"2008","unstructured":"Maurillo L, Buccisano F, Del Principe MI,  Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008;26:4944\u20134951."},{"key":"B43","series-title":"Haematologica","first-page":"605","article-title":"Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow","volume":"92","author":"Maurillo L","year":"2007","unstructured":"Maurillo L, Buccisano F, Spagnoli A,  Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. Haematologica 2007;92:605\u2013611."},{"key":"B44","series-title":"Cytometry B Clin Cytom","first-page":"91","article-title":"The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse","volume":"76","author":"Al-Mawali A","year":"2009","unstructured":"Al-Mawali A, Gillis D, Lewis I. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Cytometry B Clin Cytom 2009;76:91\u2013101."},{"key":"B45","series-title":"Blood Cancer J","first-page":"e129","article-title":"Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting","volume":"3","author":"Feller N","year":"2013","unstructured":"Feller N, van der Velden VH, Brooimans RA,  Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting. Blood Cancer J 2013;3:e129."},{"key":"B46","series-title":"Leuk Lymphoma","first-page":"80","article-title":"Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia","volume":"48","author":"Voskova D","year":"2007","unstructured":"Voskova D, Schnittger S, Schoch C,  Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia. Leuk Lymphoma 2007;48:80\u201388."},{"key":"B47","series-title":"Blood","first-page":"2213","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan E","year":"2013","unstructured":"Jourdan E, Boissel N, Chevret S,  Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 2013;121:2213\u20132223."},{"key":"B48","series-title":"Haematologica","first-page":"328","article-title":"Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial","volume":"101","author":"Willekens C","year":"2016","unstructured":"Willekens C, Blanchet O, Renneville A,  Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. Haematologica 2016;101:328\u2013335."},{"key":"B49","series-title":"Blood","first-page":"1703","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol F","year":"2018","unstructured":"Thol F, Gabdoulline R, Liebich A,  Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood 2018;132:1703\u20131713."},{"key":"B50","series-title":"Blood","first-page":"1608","article-title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group","volume":"134","author":"Rucker FG","year":"2019","unstructured":"Rucker FG, Agrawal M, Corbacioglu A,  Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. Blood 2019;134:1608\u20131618."},{"key":"B51","series-title":"Haematologica","first-page":"56","article-title":"Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia","volume":"106","author":"Puckrin R","year":"2021","unstructured":"Puckrin R, Atenafu EG, Claudio JO,  Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. Haematologica 2021;106:56\u201363."},{"key":"B52","series-title":"J Clin Oncol","first-page":"855","article-title":"Measurable residual disease response and prognosis in treatment-naive acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz KW","year":"2022","unstructured":"Pratz KW, Jonas BA, Pullarkat V,  Measurable residual disease response and prognosis in treatment-naive acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol 2022;40:855\u2013865."},{"key":"B53","series-title":"Blood","first-page":"336","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman J","year":"2024","unstructured":"Othman J, Tiong IS, O\u2019Nions J,  Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy. Blood 2024;143:336\u2013341."},{"key":"B54","series-title":"Blood","first-page":"1931","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman J","year":"2024","unstructured":"Othman J, Potter N, Ivey A,  Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 2024;143:1931\u20131936."},{"key":"B55","series-title":"J Clin Oncol","first-page":"2161","article-title":"Targeting molecular measurable residual disease and low-blast relapse in AML with venetoclax and low-dose cytarabine: a prospective phase II study (VALDAC)","volume":"42","author":"Tiong IS","year":"2024","unstructured":"Tiong IS, Hiwase DK, Abro E,  Targeting molecular measurable residual disease and low-blast relapse in AML with venetoclax and low-dose cytarabine: a prospective phase II study (VALDAC). J Clin Oncol 2024;42:2161\u20132173."},{"key":"B56","series-title":"J Clin Oncol","first-page":"2993","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert A","year":"2020","unstructured":"Burchert A, Bug G, Fritz LV,  Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol 2020;38:2993\u20133002."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/6\/article-p222.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/6\/article-p222.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/6\/article-p222.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:47:48Z","timestamp":1781527668000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/6\/article-p222.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":112,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.0028","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}